JP2017516870A5 - - Google Patents

Download PDF

Info

Publication number
JP2017516870A5
JP2017516870A5 JP2017516633A JP2017516633A JP2017516870A5 JP 2017516870 A5 JP2017516870 A5 JP 2017516870A5 JP 2017516633 A JP2017516633 A JP 2017516633A JP 2017516633 A JP2017516633 A JP 2017516633A JP 2017516870 A5 JP2017516870 A5 JP 2017516870A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutical composition
subject
antigen
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017516633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516870A (ja
JP6686007B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2015/050651 external-priority patent/WO2015187087A2/en
Publication of JP2017516870A publication Critical patent/JP2017516870A/ja
Publication of JP2017516870A5 publication Critical patent/JP2017516870A5/ja
Application granted granted Critical
Publication of JP6686007B2 publication Critical patent/JP6686007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017516633A 2014-06-04 2015-06-04 抗原ベース療法薬の新規な併用 Active JP6686007B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1450678 2014-06-04
SE1450678-6 2014-06-04
SE1451315-4 2014-11-04
SE1451315 2014-11-04
PCT/SE2015/050651 WO2015187087A2 (en) 2014-06-04 2015-06-04 Novel combinations for antigen based therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020066176A Division JP2020125300A (ja) 2014-06-04 2020-04-01 抗原ベース療法薬の新規な併用

Publications (3)

Publication Number Publication Date
JP2017516870A JP2017516870A (ja) 2017-06-22
JP2017516870A5 true JP2017516870A5 (https=) 2018-06-28
JP6686007B2 JP6686007B2 (ja) 2020-04-22

Family

ID=54767532

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017516633A Active JP6686007B2 (ja) 2014-06-04 2015-06-04 抗原ベース療法薬の新規な併用
JP2020066176A Pending JP2020125300A (ja) 2014-06-04 2020-04-01 抗原ベース療法薬の新規な併用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020066176A Pending JP2020125300A (ja) 2014-06-04 2020-04-01 抗原ベース療法薬の新規な併用

Country Status (20)

Country Link
US (3) US20170196949A1 (https=)
EP (2) EP3760224A3 (https=)
JP (2) JP6686007B2 (https=)
CN (2) CN106535926B (https=)
AU (3) AU2015268960B2 (https=)
CA (2) CA2950893C (https=)
CY (1) CY1123160T1 (https=)
DK (1) DK3151853T3 (https=)
ES (1) ES2807787T3 (https=)
HU (1) HUE051151T2 (https=)
IL (3) IL300130B2 (https=)
LT (1) LT3151853T (https=)
PL (1) PL3151853T3 (https=)
PT (1) PT3151853T (https=)
RS (1) RS60581B1 (https=)
RU (1) RU2702632C2 (https=)
SI (1) SI3151853T1 (https=)
SM (1) SMT202000384T1 (https=)
WO (1) WO2015187087A2 (https=)
ZA (1) ZA202204777B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
PL3954384T3 (pl) * 2017-09-08 2025-10-27 Diamyd Medical Ab Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy
WO2019050458A1 (en) 2017-09-08 2019-03-14 Diamyd Medical Ab IMPROVED IMMUNOTHERAPY
WO2019151939A1 (en) * 2018-02-05 2019-08-08 Diamyd Medical Ab Novel composition and use thereof
CN117599189A (zh) * 2018-03-07 2024-02-27 慧源Spv公司 用于治疗过度增殖性皮肤障碍的组合物和方法
US10500217B2 (en) 2018-04-30 2019-12-10 Leslie Ray Matthews, M.D., Llc Vitamin D3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases
WO2020210798A1 (en) * 2019-04-12 2020-10-15 Loma Linda University Methods for treatment of niemann-pick disease type c
CN116457020A (zh) * 2020-11-16 2023-07-18 W.L.戈尔及同仁股份有限公司 不含脂肪酸颗粒的制剂、方法和预填充注射装置
WO2022155188A1 (en) * 2021-01-13 2022-07-21 University Of Maryland, College Park Methods and platforms for promoting antigen-specific tolerance in the treatment of type 1 diabetes and graft rejection and compositions relating thereto
US20240277768A1 (en) * 2021-06-17 2024-08-22 Tihamer Orban Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells
WO2023066881A1 (en) * 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition of map3k15 for treating and preventing diabetes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
CA2232834A1 (en) * 1995-09-21 1997-03-27 University Of Utah Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
SE9503379D0 (sv) * 1995-09-29 1995-09-29 Synectics Medical Ab A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
CN101670119A (zh) * 2001-11-21 2010-03-17 利兰·斯坦福青年大学托管委员会 多核苷酸
US20050152914A1 (en) * 2003-06-13 2005-07-14 Diamyd, Inc. Formulation of antigen
EP1725254A4 (en) * 2004-02-04 2008-02-13 Univ Columbia ANTI-CD3 IMMUNOTHERAPY AND SPECIFIC ANTIGENS FOR THE TREATMENT OF AUTOIMMUNITY
EP1755631A2 (en) * 2004-03-03 2007-02-28 Diamyd Medical AB Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
CA2624615A1 (en) * 2005-10-05 2007-04-19 Bayhill Therapeutics, Inc. Compositions and methods for treatment of autoimmune disease
EP2118309B1 (en) * 2006-12-29 2015-01-28 The Regents of the University of Colorado, a body corporate Diagnostic and therapeutic target for autoimmune diseases and uses thereof
CN101678090B (zh) * 2007-03-07 2012-04-11 乌第有限合伙公司 用于预防和治疗自身免疫病的组合物和方法
CN101687019A (zh) * 2007-04-24 2010-03-31 迪亚米德治疗股份公司 用于治疗自身免疫性疾病和癌症的药物和方法
JP2011500569A (ja) * 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
CA2708942A1 (en) * 2007-12-19 2009-06-25 Mivac Development Aktiebolag Compositions and methods for treatment of autoimmune and allergic diseases
DK2621282T3 (da) * 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
WO2012062697A1 (en) * 2010-11-08 2012-05-18 Novartis Ag Combination therapy for type 1 diabetes
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2017516870A5 (https=)
RU2016150656A (ru) Новые комбинации для антигенной терапии
Xie et al. Enteroendocrine hormone secretion and metabolic control: importance of the region of the gut stimulation
Li et al. L-Theanine improves immunity by altering TH2/TH1 cytokine balance, brain neurotransmitters, and expression of phospholipase C in rat hearts
Chen et al. Cellular metabolic regulation in the differentiation and function of regulatory T cells
García et al. Regulation of energy expenditure and brown/beige thermogenic activity by interleukins: new roles for old actors
Colceriu-Șimon et al. The effects of non-steroidal anti-inflammatory drugs used for orthodontic pain management on tooth movement: a comprehensive review of the literature
Gallagher et al. Making progress: preserving beta cells in type 1 diabetes
Page et al. Adaptive responses in severe acute malnutrition: Endocrinology, Metabolomics, Mortality, and growth
Cook et al. Prospects of a type 1 diabetes vaccine
Juedes et al. Regulatory T‐cells in type 1 diabetes
Wehrens et al. Treating arthritis by immunomodulation: is there a role for regulatory T cells?
US20200138920A1 (en) Novel Combinations for Antigen Based Therapy
HRP20201030T1 (hr) Dekarboksilaza glutaminske kiseline (gad) za uporabu za liječenje autoimune bolesti
Fabbrini et al. Soluble and controlled-release preparations of levodopa: do we really need them?
JP2928608B2 (ja) インスリン依存型糖尿病予防または治療剤
RU2824503C2 (ru) Новые комбинации для антигенной терапии
Van et al. All-trans retinoic acids inhibits type 1 diabetes by Treg-dependent suppression of IFN-γ-producing-T-cells without affecting Th17 cells
Singh et al. Therapeutic Perspectives in Type-1 Diabetes
Sonino et al. Long-Acting Octreotide LAR Compared with Lanreotide SR in the Treatment of Acromegaly
Pepall Project seahorse: conserving the oceans’ medicinal resources
Oku et al. MAINTENANCE OF TREG POPULATION AND PROLONGATION OF ALLOGRAFT SURVIVAL BY HEPATOCYTE GROWTH FACTOR IN MHC-INBRED CLAWN MINIATURE SWINE: 22
Brugman et al. Neonatal oral administration of DiaPep277 combined with hydrolyzed casein diet protects against type 1 diabetes. An experimental study.